Novo Nordisk [NVO] announced on Wednesday, that it has received a significant boost after the National Institute for Health and Care Excellence recommended broader use of Wegovy to help prevent heart attacks and strokes in adults at high cardiovascular risk.
The decision makes Wegovy the first GLP-1 medicine in England approved specifically for reducing future cardiovascular events in overweight or obese patients who have already experienced serious circulatory conditions.
The guidance is expected to expand treatment access through the National Health Service, with an estimated 1.2 million people potentially eligible.
Clinical trial data showed semaglutide, the active ingredient in Wegovy, reduced the risk of major cardiovascular events by 20 percent when used alongside existing heart medicines.
Health officials said the recommendation reflects growing evidence that GLP-1 therapies provide benefits beyond weight loss, offering patients an added layer of protection against recurring cardiovascular disease.
NVO is currently trading at $36.72, down $0.03 or 0.08 percent on the New York Stock Exchange.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.